Event in Progress:
Discover the latest content that has just been published on Research Tree
Amgen had an eventful 2022. The company carried out some major acquisitions in the year including the $3.7 billion purchase of ChemoCentryx followed by the even bigger, $27.8 billion acquisition of Horizon Therapeutics. The company’s financial performance in the last quarter was also strong as its growing general medicine and hematology-oncology brands experienced significant volume increases. With the introduction of TEZSPIRE and the acquisition of TAVNEOS, two first-in-class medications that t
Companies: AMGEN (AMGN:NYSE)Amgen Inc. (AMGN:NAS)
Baptista Research
Despite the challenges in the macroeconomic environment and the pharmaceutical business, Amgen’s stock has been on a strong upward trajectory over the past weeks. The company delivered a solid result where it surpassed Wall Street expectations on all counts. Volumes increased by 8% and 16% outside of the United States in Q3, showing the benefit of that strategy. During the quarter, they closed the acquisition of ChemoCentryx and included Tavneos, a drug used to treat anti-neutrophil cytoplasmic
Amgen delivered strong volume-driven growth in the last quarter which resulted in the company managing an all-around beat. Many of the innovative products of the company performed quite well, namely Evenity, Prolia, Otezia, and Repatha, all of which delivered sales growth of double-digits. Two of the company's new products, Tezspire and Lumakras, are both off to a great start. Lumakras is being prescribed to patients with non-small cell cancer worldwide. Meanwhile, Tezspire has made a large impa
Companies: Amgen Inc. (AMGN:NAS)Amgen Inc. (0R0T:LON)
Amgen started off with 2022 on a positive note generating 6% revenue growth and 15% earnings per share growth. The company’s drugs Repatha, Prolia, and Evenity were responsible for a 9% increase in product sales. However, the company’s net selling price declined, and foreign exchange headwinds partially offset volume growth. Amgen also saw strong volume growth outside of the United States of 15% in Q1 and nearly 30% volume growth in the Asia Pacific region, which is an important component of its
Biogen has been going through a rough patch off-late. One of its core drugs, Tecifidera's revenue continued to erode in the U.S. due to generic entry. In light of several recent challenges, the company announced that it would implement cost-cutting measures expected to save approximately $500 million annually. On the other hand, they recently announced a deal to sell their Samsung Bioepis joint venture stake to Samsung Biologics, with Biogen continuing to be the commercialization partner for the
Amgen has continued to benefit from strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings. The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests. Teneobio's acquisition, when combined with Nuevolution's DNA encoded library technology, gives Amgen the ability to develop both large and small molecule multi-specifics. Besides, The compan
Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings. The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests. Teneobio's acquisition, when combined with Nuevolution's DNA encoded library technology, gives the company the ability to dev
Amgen experienced another solid quarter of growth, with total revenues increasing by 4%, driven by volume growth of 8%. The robust performance was a result of strong global demand for many of its innovative offerings such as Repatha and Prolia, as well as its high-quality biosimilars. Besides, the management is excited about tezepelumab, a first-in-class treatment for severe asthma that they are looking to launch in the U.S. in 2022. Given the loads of patients for whom current asthma treatments
Amgen continued to witness a decent top-line growth despite the lingering effects of the pandemic driven by the gradually increasing demand for its offerings. The company’s total revenue grew by 5% in Q2 compared to the previous year and 11% compared to the previous quarter. Its performance in non-U.S. markets was noteworthy and saw a 22% volume growth. Biosimilars were also a major contributor to the top-line. Sadly, a trimmed guidance for the rest of 2021 resulted in the stock price witnessing
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc
Companies: IMM IBAB 0O8G BCART 0QLR RHO5 MRCK 0QXH VSC 0QGJ SANO 0OCQ IPH GSK AZN 0Y6X QGEN 0HL9 0GRZ EJXB 0Q15 ABBV 0HAV 0RIH 0R0T BMYS EXK 0J8Z 0R29 0R34 0K3W NSTGQ 0KCC 0Q1N SGEN 0R0H 12V VNRX XE9
goetzpartners securities Limited
Stocks in the life sciences industry have struggled to regain their sparkle following the autumn 2015 sell off triggered by Hilary Clinton’s comments on drug pricing with the NASDAQ Biotechnology Index down some 22% since the beginning of the year. Indeed both sides of the presidential race have now targeted pharmaceutical companies with Donald Trump campaigning for price negotiations between drug manufacturers and Medicare
Companies: PLI SAR BLU SKP INS SCLP HVO OXB OPTI ONC HCM 0R0T 0HNC 0L35 1S9
Hybridan
Research Tree provides access to ongoing research coverage, media content and regulatory news on Amgen Inc.. We currently have 0 research reports from 5 professional analysts.
Cambridge Nutritional Sciences (CNS) has provided a trading update for the 12 months to 31 March 2024, noting that a combination of strong sales growth and significant margin improvements, driven by operational efficiencies, have played key factors in the group’s expectation of being adjusted EBITDA positive in FY 2024. Revenues are expected to be £9.8m (30% YoY growth), ahead of our £9.0m forecast, with gross profits expected to exceed £6m, which is again ahead of our year-end forecast of £5.6m
Companies: Cambridge Nutritional Sciences PLC
Cavendish
Companies: Warpaint London PLC
Shore Capital
Cambridge Nutritional Sciences (CNS) has published its H1 2024 results to end September 2023. Group revenues grew 44% to £4.9m and gross profits increased by 63% to £3.1m, with the company benefitting from newfound operational efficiencies. With its now streamlined strategy focussing on the core Health & Nutrition business and the initial signs of an encouraging uptick in sales momentum, we believe the company is well positioned for growth that will help create future value for shareholders. We
22nd April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi
Companies: ARV CTL AFRN FEN HUW TENG BBSN EAAS VAL
Companies: IGP RUA BOOM
Feature article: Steady as she goes, but could be better: A review of investment company liquidity since 2016 Liquidity is the lifeblood of equity markets. The measurement of liquid asset availability to a market or company is a way of gauging a market’s health. This article builds on our previous work, which analysed the liquidity data for non-financial trading companies, by applying the same analytical techniques to the investment companies (IC) space. We analyse liquidity for ICs as a whol
Companies: NBPE ICGT ARBB RECI CLIG HAT AVO VTA APAX
Hardman & Co
17th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi
Companies: ARS TIDE SCE SNX ECK CNS TST SPEC SSTY
Venture Life has reported FY23 results to December 2023, following the February trading update. Revenues grew 17% in the year to £51.4m (our est. £50.7m) and adjusted EBITDA was £11.6m (our est. £11.6m). Cash conversion was 85%, generating £9.8m of cash from operations. Cash generation and no M&A in 2023 allowed the company to de-lever, closing FY23 with net debt to adjusted EBITDA at 1.3x. Management have focused on growth with three therapy areas generating double-digit revenue growth and onli
Companies: Venture Life Group Plc
At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies to address serious fungal and bacterial infections. It continues to make advancements in this specialised segment through the development of opportunistic acquisitions leveraging its anti-infective expertise. Its growth initiatives remain funded through the traction of its commercialised products, Cresemba and Zevtera. FY24 key strategic priorities inc
Companies: Basilea Pharmaceutica AG
Edison
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Companies: BILN IGP RBN SBTX
Companies: PureTech Health PLC
Liberum
Creo Medical has received US FDA approval for its Speedboat UltraSlim device, which will enable the company to launch it in the coveted US market. Though expected, this marks a material regulatory win for Creo as UltraSlim is the company’s thinnest and most versatile device and it is now projected to be available in both Europe (via accelerated EU regulatory pathway) and the US in 2024. The UltraSlim device remains an important addition to the portfolio as it provides broader access to gastroint
Companies: Creo Medical Group Plc
Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of lung cancer. While implementing this strategy over the past year, Cizzle’s interest has been broadened to include early detection of other cancers and companion diagnostic tests that can assist in the development and use of personalised medicines. In the 12 months since listing, Cizzle has secured key partners
Companies: Cizzle Biotechnology Holdings PLC
Dish of the day Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** 9 November: Chapel Down Group ITF: England's leading and largest wine producer with an award-winning range of sparkling and still wines, under the Chapel Down brand. The Company owns, leases and sources from 1,023 acres of vineyards in South East England announces its Admission to AIM after its transfer from the Aquis Apex market. The Company will not be raising new capital or providing a s
Companies: CLBS NTBR YNGA TGP MANO POLB AURR
Share: